Literature DB >> 12944480

E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas.

Ulrike Ziebold1, Eunice Y Lee, Roderick T Bronson, Jacqueline A Lees.   

Abstract

The E2F transcription factors are key downstream targets of the retinoblastoma protein (pRB) tumor suppressor. We have previously shown that E2F3 plays a critical role in mediating the mitogen-induced activation of E2F-responsive genes and contributes to both the inappropriate proliferation and the p53-dependent apoptosis that arise in pRB-deficient embryos. Here we show that E2F3 also has a significant effect on the phenotype of tumor-prone Rb(+/-) mice. The absence of E2F3 results in a significant expansion in the life spans of these animals that correlates with a dramatic alteration in the tumor spectrum. E2F3 loss suppresses the development of the pituitary tumors that normally account for the death of Rb(+/-) mice. However, it also promotes the development of medullary thyroid carcinomas yielding metastases at a high frequency. This increased aggressiveness does not seem to result from any change in p53 levels or activity in these tumors. We show that, instead, E2F3 loss leads to an increase in the rate of tumor initiation. Finally, analysis of Rb(+/-); E2f3(+/-) mice shows that this tumor-suppressive function of E2F3 is dose dependent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944480      PMCID: PMC193688          DOI: 10.1128/MCB.23.18.6542-6552.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex.

Authors:  Joseph B Rayman; Yasuhiko Takahashi; Vahan B Indjeian; Jan-Hermen Dannenberg; Steven Catchpole; Roger J Watson; Hein te Riele; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-04-15       Impact factor: 11.361

2.  Inactivation of E2F3 results in centrosome amplification.

Authors:  Harold I Saavedra; Baidehi Maiti; Cynthia Timmers; Rachel Altura; Yukari Tokuyama; Kenji Fukasawa; Gustavo Leone
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

3.  E2F4 loss suppresses tumorigenesis in Rb mutant mice.

Authors:  Eunice Y Lee; Hieu Cam; Ulrike Ziebold; Joseph B Rayman; Jacqueline A Lees; Brian David Dynlacht
Journal:  Cancer Cell       Date:  2002-12       Impact factor: 31.743

4.  p53 and E2F-1 cooperate to mediate apoptosis.

Authors:  X Wu; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 5.  The retinoblastoma gene and gene product.

Authors:  R A Weinberg
Journal:  Cancer Surv       Date:  1992

6.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis.

Authors:  E Y Lee; C Y Chang; N Hu; Y C Wang; C C Lai; K Herrup; W H Lee; A Bradley
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

7.  Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells.

Authors:  Marc Vooijs; Hein te Riele; Martin van der Valk; Anton Berns
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

8.  Structural evidence for the authenticity of the human retinoblastoma gene.

Authors:  Y K Fung; A L Murphree; A T'Ang; J Qian; S H Hinrichs; W F Benedict
Journal:  Science       Date:  1987-06-26       Impact factor: 47.728

9.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence.

Authors:  W H Lee; R Bookstein; F Hong; L J Young; J Y Shew; E Y Lee
Journal:  Science       Date:  1987-03-13       Impact factor: 47.728

10.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

Authors:  S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

View more
  49 in total

1.  Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression.

Authors:  Chiaki Takahashi; Bernardo Contreras; Roderick T Bronson; Massimo Loda; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 2.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

3.  Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice.

Authors:  Takeshi Suzuki; Ken-ichi Minehata; Keiko Akagi; Nancy A Jenkins; Neal G Copeland
Journal:  EMBO J       Date:  2006-07-06       Impact factor: 11.598

4.  Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Authors:  C D Hurst; D C Tomlinson; S V Williams; F M Platt; M A Knowles
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

5.  APC/C (Cdh1) controls the proteasome-mediated degradation of E2F3 during cell cycle exit.

Authors:  Zhen Ping; Ratna Lim; Tarig Bashir; Michele Pagano; Daniele Guardavaccaro
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

6.  Concomitant inactivation of Rb and E2f8 in hematopoietic stem cells synergizes to induce severe anemia.

Authors:  Tinghui Hu; Seda Ghazaryan; Chandler Sy; Charles Wiedmeyer; Victor Chang; Lizhao Wu
Journal:  Blood       Date:  2012-03-14       Impact factor: 22.113

7.  E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity.

Authors:  P S Danielian; L B Friesenhahn; A M Faust; J C West; A M Caron; R T Bronson; J A Lees
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

8.  Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.

Authors:  Hongbo Wang; Frederick Bauzon; Peng Ji; Xiaoliang Xu; Daqian Sun; Joseph Locker; Rani S Sellers; Keiko Nakayama; Keiich I Nakayama; David Cobrinik; Liang Zhu
Journal:  Nat Genet       Date:  2009-12-06       Impact factor: 38.330

Review 9.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

10.  Tuberous sclerosis complex 1 regulates dE2F1 expression during development and cooperates with RBF1 to control proliferation and survival.

Authors:  Ting-Chiu Hsieh; Brandon N Nicolay; Maxim V Frolov; Nam-Sung Moon
Journal:  PLoS Genet       Date:  2010-08-19       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.